Broadwood Partners Reiterates Opposition to STAAR Surgical’s Sale to Alcon Following Conclusion of Performative Go-Shop Process

Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood,” “we,” “us,” or “our”) today issued the following open letter to the shareholders of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA). Broadwood, which owns 30.2% of STAAR’s outstanding common stock, continues to oppose the proposed sale of the Company to Alcon Inc. (“Alcon”) (NYSE: ALC) on transaction terms that remain unchanged following the conclusion of the Company’s flawed and belated go-shop process.

The full text of Broadwood’s letter is below. Shareholders can find additional information at www.LetSTAARShine.com.

* * *

December 8, 2025

Dear Fellow STAAR Surgical Shareholders,

Broadwood Partners, L.P. and its affiliates have been investors in STAAR Surgical Company for more than thirty years due to our long-held belief that the Company has an opportunity to be the leader in the global refractive surgery market and drive profitable growth and significant long-term value.

While we are not opposed to a sale of the Company in principle, we were disappointed that STAAR’s Board of Directors made the consequential decision in August 2025 to sell the Company to Alcon at what we believe was a uniquely inopportune time, at a price that does not reflect the intrinsic value of the business and following a hasty and limited sale process. Alcon was willing to pay approximately twice as much per share on two occasions in 2024, according to STAAR’s filings.

It was less than 50 days ago that shareholders were poised to overwhelmingly reject the ill-conceived, deeply flawed transaction. Then, the Board postponed the shareholder vote on the sale three times and announced it would conduct an after-the-fact, perfunctory go-shop process, apparently in the hope that doing so would cure the egregious process, timing, and pricing flaws of the original transaction. The Board promised that, for the first time, the Company would solicit alternative proposals from parties other than Alcon.

We urged the Board to appoint new directors to help oversee this process and to give shareholders confidence that it would be conducted objectively and fairly. The Board refused.

Today, the Board proved once again that shareholders cannot rely on its judgment and oversight. The Board reported that its go-shop process did not yield a better offer and that therefore the Alcon deal represents fair value.